Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol

INTRODUCTION: Regorafenib was recently approved for patients with pretreated advanced colorectal cancer (aCRC), despite a moderate improvement of the patients’ outcome, and significant toxicities. Based on previous studies showing that early fluorodeoxyglucose-positron emission tomography (FDG-PET)-...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMJ Open
Autori principali: Hendlisz, Alain, Deleporte, Amélie, Vandeputte, Caroline, Charette, Nicolas, Paesmans, Marianne, Guiot, Thomas, Garcia, Camilo, Flamen, Patrick
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2015
Soggetti:
Oncology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4360786/
https://ncbi.nlm.nih.gov/pubmed/25753361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2014-007189
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi